Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.
2.

Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.

Beggs AD, Dilworth MP, Domingo E, Midgley R, Kerr D, Tomlinson IP, Middleton GW.

Oncoscience. 2015 Mar 23;2(5):508-16. eCollection 2015.

3.

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.

Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom KJ, Salmon A, D'Silva O, Betteridge KB, Williams AC, Kerr DJ, Salmon AH, Oltean S, Midgley RS, Ladomery MR, Harper SJ, Varey AH, Bates DO.

Mol Oncol. 2015 Jan;9(1):167-78. doi: 10.1016/j.molonc.2014.07.017. Epub 2014 Aug 20.

4.

Intranasal peptide-induced tolerance and linked suppression: consequences of complement deficiency.

Fossati-Jimack L, Ling GS, Baudino L, Szajna M, Manivannan K, Zhao JC, Midgley R, Chai JG, Simpson E, Botto M, Scott D.

Immunology. 2015 Jan;144(1):149-57. doi: 10.1111/imm.12358.

5.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I.

J Clin Oncol. 2014 Apr 1;32(10):1031-9. doi: 10.1200/JCO.2013.51.1857. Epub 2014 Mar 3. Review.

6.

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R.

J Clin Oncol. 2013 Dec 1;31(34):4297-305. doi: 10.1200/JCO.2013.50.0322. Epub 2013 Sep 23.

PMID:
24062397
7.

TGF-β: an emerging player in drug resistance.

Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R.

Cell Cycle. 2013 Sep 15;12(18):2960-8. doi: 10.4161/cc.26034. Epub 2013 Aug 12.

8.

A role for endoplasmic reticulum exit sites in foot-and-mouth disease virus infection.

Midgley R, Moffat K, Berryman S, Hawes P, Simpson J, Fullen D, Stephens DJ, Burman A, Jackson T.

J Gen Virol. 2013 Dec;94(Pt 12):2636-46. doi: 10.1099/vir.0.055442-0. Epub 2013 Aug 20.

9.

Stage II colon cancer.

Church DN, Midgley R, Kerr DJ.

Chin Clin Oncol. 2013 Jun;2(2):16. doi: 10.3978/j.issn.2304-3865.2013.03.03.

10.

Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.

Midgley RS, Kerr DJ.

J Clin Oncol. 2013 Apr 20;31(12):1611. doi: 10.1200/JCO.2012.47.2852. Epub 2013 Mar 18. No abstract available.

PMID:
23509312
11.

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Brady J, Corrie P, Chau I, Digumarti R, Adams LM, Botbyl J, Laubscher KH, Midgley RS, Mallath M.

Invest New Drugs. 2013 Oct;31(5):1228-35. doi: 10.1007/s10637-013-9938-7. Epub 2013 Feb 28.

PMID:
23456563
12.

Biomarkers in early-stage colorectal cancer: ready for prime time?

Church D, Midgley R, Kerr D.

Dig Dis. 2012;30 Suppl 2:27-33. doi: 10.1159/000341890. Epub 2012 Nov 23. Review.

PMID:
23207929
13.

Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson I.

J Pathol. 2013 Feb;229(3):441-8. doi: 10.1002/path.4139.

14.

Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.

Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP.

Oncotarget. 2012 Nov;3(11):1348-55.

15.

Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer.

Lefevre JH, Bonilla C, Colas C, Winney B, Johnstone E, Tonks S, Day T, Hutnik K, Boumertit A, Soubrier F, Midgley R, Kerr D, Parc Y, Bodmer WF.

J Hum Genet. 2012 Nov 26;57(11):709-716. doi: 10.1038/jhg.2012.99. Epub 2012 Aug 9.

16.

The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE.

Ann Oncol. 2013 Jan;24(1):179-85. doi: 10.1093/annonc/mds246. Epub 2012 Aug 2.

PMID:
22865778
17.

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI.

Invest New Drugs. 2013 Apr;31(2):370-80. doi: 10.1007/s10637-012-9825-7. Epub 2012 Jun 2.

PMID:
22661287
18.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

19.

TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres.

Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, Howarth K, Ballereau S, Hodgson SV, Zauber A, Bertagnolli M, Midgley R, Campbell H, Kerr D, Dunlop MG, Tomlinson IP.

Gut. 2012 Feb;61(2):248-54. doi: 10.1136/gut.2011.239772. Epub 2011 Jun 27.

20.

The emergence of 'omics for the management of colorectal cancer.

Midgley RS, Church D, Kerr DJ.

Curr Opin Oncol. 2011 Jul;23(4):410-4. doi: 10.1097/CCO.0b013e328347ae49. Review.

PMID:
21577111
21.

KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.

Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans PM, Pick AW, Knight S, Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM.

Clin Cancer Res. 2011 Mar 1;17(5):1122-30. doi: 10.1158/1078-0432.CCR-10-1720. Epub 2011 Jan 14.

22.

Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients.

Bonilla C, Lefèvre JH, Winney B, Johnstone E, Tonks S, Colas C, Day T, Hutnik K, Boumertit A, Midgley R, Kerr D, Parc Y, Bodmer WF.

J Hum Genet. 2011 Jan;56(1):58-63. doi: 10.1038/jhg.2010.144. Epub 2010 Nov 25.

23.

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.

Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, Spain SL, Broderick P, Domingo E, Farrington S, Prendergast JG, Pittman AM, Theodoratou E, Smith CG, Olver B, Walther A, Barnetson RA, Churchman M, Jaeger EE, Penegar S, Barclay E, Martin L, Gorman M, Mager R, Johnstone E, Midgley R, Niittymäki I, Tuupanen S, Colley J, Idziaszczyk S; COGENT Consortium, Thomas HJ, Lucassen AM, Evans DG, Maher ER; CORGI Consortium; COIN Collaborative Group; COINB Collaborative Group, Maughan T, Dimas A, Dermitzakis E, Cazier JB, Aaltonen LA, Pharoah P, Kerr DJ, Carvajal-Carmona LG, Campbell H, Dunlop MG, Tomlinson IP.

Nat Genet. 2010 Nov;42(11):973-7. doi: 10.1038/ng.670. Epub 2010 Oct 24.

24.

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?

Yanagisawa Y, Midgley RS.

Nat Rev Clin Oncol. 2010 Oct;7(10):556-7. doi: 10.1038/nrclinonc.2010.140. No abstract available.

PMID:
20877418
25.

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ.

J Clin Oncol. 2010 Oct 20;28(30):4575-80. doi: 10.1200/JCO.2010.29.6244. Epub 2010 Sep 13.

PMID:
20837956
26.

Can we treat cancer for a dollar a day? Guidelines for low-income countries.

Kerr DJ, Midgley R.

N Engl J Med. 2010 Aug 26;363(9):801-3. doi: 10.1056/NEJMp1002812. No abstract available.

PMID:
20818843
27.

Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Spanswick VJ, Davies S, Hartley JA, Kerr DJ.

Sci Transl Med. 2010 Jul 14;2(40):40ra50. doi: 10.1126/scitranslmed.3000615.

28.

Gene profiling in early stage disease.

Midgley R, Rasul K, Al Salama H, Kerr DJ.

Cancer J. 2010 May-Jun;16(3):210-3. doi: 10.1097/PPO.0b013e3181e07606. Review.

PMID:
20526098
29.

Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

Kerr DJ, Midgley R.

J Clin Oncol. 2010 Jul 10;28(20):3210-2. doi: 10.1200/JCO.2010.28.9322. Epub 2010 May 24. No abstract available.

PMID:
20498404
30.

Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver.

Pwint TP, Midgley R, Kerr DJ.

Semin Oncol. 2010 Apr;37(2):149-59. doi: 10.1053/j.seminoncol.2010.03.005. Review.

PMID:
20494707
31.

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

Sabharwal A, Corrie PG, Midgley RS, Palmer C, Brady J, Mortimer P, Watson AJ, Margison GP, Middleton MR.

Cancer Chemother Pharmacol. 2010 Oct;66(5):829-35. doi: 10.1007/s00280-009-1225-0. Epub 2009 Dec 29.

PMID:
20039040
32.

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI.

Ann Oncol. 2010 Apr;21(4):884-94. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13.

33.

Genetic prognostic and predictive markers in colorectal cancer.

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D.

Nat Rev Cancer. 2009 Jul;9(7):489-99. doi: 10.1038/nrc2645. Epub 2009 Jun 18. Review. Erratum in: Nat Rev Cancer. 2011 Apr;11(4):309.

PMID:
19536109
34.

Evolution of nonsurgical therapy for colorectal cancer.

Midgley RS, Yanagisawa Y, Kerr DJ.

Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20. doi: 10.1038/ncpgasthep1337. Epub 2009 Jan 20. Review.

PMID:
19153564
35.

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH.

Hepatology. 2009 Jan;49(1):124-32. doi: 10.1002/hep.22626.

PMID:
18980227
36.

Capecitabine: have we got the dose right?

Midgley R, Kerr DJ.

Nat Clin Pract Oncol. 2009 Jan;6(1):17-24. doi: 10.1038/ncponc1240. Epub 2008 Oct 21. Review.

PMID:
18936793
37.

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR.

Br J Cancer. 2008 May 20;98(10):1614-8. doi: 10.1038/sj.bjc.6604366. Epub 2008 May 13. Erratum in: Br J Cancer. 2009 Aug 4;101(3):550.

38.

Genetic characterization and molecular epidemiology of foot-and-mouth disease viruses isolated from Afghanistan in 2003-2005.

Schumann KR, Knowles NJ, Davies PR, Midgley RJ, Valarcher JF, Raoufi AQ, McKenna TS, Hurtle W, Burans JP, Martin BM, Rodriguez LL, Beckham TR.

Virus Genes. 2008 Apr;36(2):401-13. doi: 10.1007/s11262-008-0206-4. Epub 2008 Feb 16.

PMID:
18278548
39.

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, Smith DA, Versola M, Fleming RA, Ward C, O'Dwyer PJ, Middleton MR.

Ann Oncol. 2007 Dec;18(12):2025-9. Epub 2007 Sep 9.

PMID:
17846021
40.

Evaluating the ability of visual images to inform college women about the link between smoking and cervical intraepithelial neoplasia (CIN) and to motivate quitting: critical dimensions.

Lee KM, Saules KK, Pomerleau CS, Opipari AW, Snedecor SM, Sen A, Vannest N, Midgley R, Kleinsmith L.

J Cancer Educ. 2007 Fall;22(3):154-8.

PMID:
17760520
41.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.

42.

Pandemic strain of foot-and-mouth disease virus serotype O.

Knowles NJ, Samuel AR, Davies PR, Midgley RJ, Valarcher JF.

Emerg Infect Dis. 2005 Dec;11(12):1887-93.

43.

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Midgley R, Kerr DJ.

Nat Clin Pract Oncol. 2005 Jul;2(7):364-9. Review.

PMID:
16075796
44.

Bevacizumab--current status and future directions.

Midgley R, Kerr D.

Ann Oncol. 2005 Jul;16(7):999-1004. Epub 2005 Jun 6. Review.

PMID:
15939715
45.

Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study.

Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, Finkelstein JS, Greendale GA, Kelsey J, Korenman S, Luborsky JL, Matthews K, Midgley R, Powell L, Sabatine J, Schocken M, Sowers MF, Weiss G.

J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31.

PMID:
15181033
47.

HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ, Rickinson AB.

J Virol. 2003 Nov;77(21):11507-16.

48.

Colorectal cancer.

Nicum S, Midgley R, Kerr DJ.

Acta Oncol. 2003;42(4):263-75. Review.

PMID:
12899497
49.

Immunotherapy for colorectal cancer.

Midgley RS, Kerr DJ.

Expert Rev Anticancer Ther. 2003 Feb;3(1):63-78. Review.

PMID:
12597351
50.

Ras as a target in cancer therapy.

Midgley RS, Kerr DJ.

Crit Rev Oncol Hematol. 2002 Nov;44(2):109-20. Review.

PMID:
12413630

Supplemental Content

Loading ...
Support Center